New Data Supports Medtronic’s Next-Gen MiniMed 780G Insulin Pump

Medtronic released positive real-world data that supported its next-gen MiniMed 780G insulin pump system at the American Diabetes Association (ADA) annual meeting. MiniMed 780G is an advanced hybrid closed-loop system with meal detection tech that automatically adjusts and corrects glucose levels every five minutes.
 
The system showed improvements in glycemic outcomes that met consensus guideline recommendations of 70% time in range with less user interaction.
 
Real-world data from Europe and Chile was presented. In Europe, results from 7,346 people using MiniMed 780G with the Guardian 4 CGM sensor showed improved user experience and strong glycemic outcomes. A second evaluation of 674 European users compared results for those using MiniMed 780G with the Guardian 4 sensor who before used Guardian 3—it was found the Guardian 4 sensor reduced SmartGuard exits and fingersticks.
 
Overall time in rage (TIR) was 72.9%, and GMI was 6.98%. Those with recommended settings achieved the highest TIR (78.8%) and lowest time below range (TBR) (1.8%).
 
Medtronic also presented data from 37 system users with type 1 diabetes in Chile. Average TIR was 78.4%, average GMI was under 7%, and 77% of study targets had TIR over 70% and GMI under 7%.
 
Lastly, data from 176 patients who continued using MiniMed 780G with Guardian 4 after the U.S. pivotal trial was shared. At three months with recommended settings, HbA1C was 7.1% overall, TIR was 74.7%, and TBR was 2.1%.
 
MiniMed 780G is now available in over 40 countries and is being reviewed by the U.S. Food and Drug Administration (FDA) for approval.